• Access To Medicines

Press Release: Over £100m cash boost to manufacture millions of doses of COVID-19 vaccine

- New state-of-the-art centre to scale up COVID-19 vaccine and gene therapy manufacturing gets £100m investment - Additional £4.7m for new training facilities and an online learning platform to boost vaccine as well as cell and gene therapy skills - New centre and skills vital for the UK’s ability respond to diseases like coronavirus, and potential future pandemics

CGT Catapult Annual Review 2020 highlights impact on growth and productivity in the UK cell and gene therapy industry

The 2020 annual report released today presents Cell and Gene Therapy Catapult's achievements, collaborations and initiatives from the past year and their impact in enhancing growth, productivity and supporting the development and commercialisation of cell and gene therapies.

Life Sciences Recovery Roadmap

The COVID-19 crisis has powerfully demonstrated the strategic importance of the life science sector to the UK’s health, security, and to the economy.

Fieldfisher Life Sciences sector group advise on £48 million fundraise by AIM listed Avacta Group plc to fund COVID-19 test

European law firm Fieldfisher has advised finnCap and Zeus Capital, in their capacities as joint brokers to AIM-listed Avacta Group plc, a leading life sciences company, on its heavily oversubscribed £48 million fundraising to develop a saliva-based rapid antigen COVID-19 test.

Achilles Therapeutics to set up manufacturing operations at the CGT Catapult manufacturing centre

The collaboration will see Achilles Therapeutics expand their manufacturing footprint at the CGT Catapult manufacturing centre to supply clinical trials of their novel T cell therapy products. Onboarding has begun into one of the newly operational modules at the state-of-the-art facility.

CiRA Foundation and the Cell and Gene Therapy Catapult set to launch new stem cell collaborative research

The companies will combine their expertise to explore novel methods to characterise pluripotent stem cells for the manufacture of regenerative medicine products.

Fieldfisher Life Sciences sector group mobilises to offer pro bono legal advice for COVID-19

Fieldfisher are delighted to announce that their pan-European Life Sciences sector group have mobilised to show support for life science companies contributing efforts towards global pandemic COVID-19.

Gene therapy: the challenge and the opportunity

By Annie Zeng Gene therapy is an experimental and therapeutic technique involving the engineering of genes with the hope to cure disease at its root cause. This has become an increasingly buoyant area for investment and although still at an early phase of development, there have been recent approvals of clinical and commercial gene therapies for use in humans.

Enterprise Therapeutics appoints Dr David Morris MD as Chief Medical Officer

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering with respiratory disease, today announced it has appointed Dr David Morris MD as Chief Medical Officer to lead the Company’s respiratory programmes.

Impact of the ATTC Network after 18 months of operation

Just 18 months ago, the Advanced Therapy Treatment Centre (ATTC) network was set up through funding from the UK Research and Innovation Industrial Strategy Challenge Fund.